- Home
- STTK vs HHS Comparison
STTK vs HHS Comparison
Compare STTK & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- HHS
- Stock Information
- Founded
- STTK 2016
- HHS 1923
- Country
- STTK United States
- HHS United States
- Employees
- STTK N/A
- HHS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- HHS Advertising
- Sector
- STTK Health Care
- HHS Consumer Discretionary
- Exchange
- STTK Nasdaq
- HHS Nasdaq
- Market Cap
- STTK 37.6M
- HHS 37.0M
- IPO Year
- STTK 2020
- HHS N/A
- Fundamental
- Price
- STTK $0.91
- HHS $4.60
- Analyst Decision
- STTK Hold
- HHS
- Analyst Count
- STTK 4
- HHS 0
- Target Price
- STTK $3.00
- HHS N/A
- AVG Volume (30 Days)
- STTK 108.4K
- HHS 23.3K
- Earning Date
- STTK 05-01-2025
- HHS 05-23-2025
- Dividend Yield
- STTK N/A
- HHS N/A
- EPS Growth
- STTK N/A
- HHS N/A
- EPS
- STTK N/A
- HHS N/A
- Revenue
- STTK $4,606,000.00
- HHS $185,242,000.00
- Revenue This Year
- STTK N/A
- HHS $6.54
- Revenue Next Year
- STTK N/A
- HHS N/A
- P/E Ratio
- STTK N/A
- HHS N/A
- Revenue Growth
- STTK 69.65
- HHS N/A
- 52 Week Low
- STTK $0.69
- HHS $4.27
- 52 Week High
- STTK $11.76
- HHS $8.87
- Technical
- Relative Strength Index (RSI)
- STTK 47.64
- HHS 47.91
- Support Level
- STTK $0.84
- HHS $4.44
- Resistance Level
- STTK $1.00
- HHS $5.06
- Average True Range (ATR)
- STTK 0.09
- HHS 0.33
- MACD
- STTK 0.01
- HHS -0.02
- Stochastic Oscillator
- STTK 42.02
- HHS 30.38
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.